Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Deciphera Pharmaceuticals, Inc. (DCPH)  
$25.36 0.01 (0.04%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 60,930,000
Market Cap: 1.55(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $10.11 - $25.38
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. In addition, Co. has identified and developed various product candidates from its platform into clinical studies, including vimseltinib and DCC-3116. Co. is studying vimseltinib in a Phase 3 study in patients with tenosynovial giant cell tumor. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 10,000 1,687,666
Total Buy Value $0 $0 $138,828 $30,291,232
Total People Bought 0 0 1 3
Total Buy Transactions 0 0 1 3
Total Shares Sold 10,159 75,715 115,161 179,650
Total Sell Value $158,659 $1,108,986 $1,602,723 $2,646,007
Total People Sold 4 5 6 6
Total Sell Transactions 4 14 25 43
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 290
  Page 8 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Morl Christopher John Chief Business Officer   •       –      –    2020-01-07 4 AS $60.02 $99,035 D/D (1,650) 0 -16%     
   Morl Christopher John Chief Business Officer   •       –      –    2020-01-07 4 OE $3.95 $6,518 D/D 1,650 1,650     -
   Bristol James Arthur Director   –       •      –    2020-01-03 4 AS $55.96 $458,195 D/D (7,989) 0 -22%     
   Bristol James Arthur Director   –       •      –    2020-01-03 4 OE $1.89 $15,099 D/D 7,989 7,989     -
   Taylor Michael Douglas Director   –       •      –    2020-01-03 4 AS $56.01 $1,800,923 D/D (31,422) 0 -22%     
   Taylor Michael Douglas Director   –       •      –    2020-01-03 4 OE $1.89 $59,388 D/D 31,422 31,422     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2020-01-03 4 AS $56.26 $249,993 D/D (4,359) 0 -22%     
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2020-01-03 4 OE $1.89 $8,239 D/D 4,359 4,359     -
   Morl Christopher John Chief Business Officer   •       –      –    2020-01-02 4 AS $57.74 $944,872 D/D (16,137) 0 -11%     
   Morl Christopher John Chief Business Officer   •       –      –    2020-01-02 4 OE $3.95 $63,741 D/D 16,137 16,137     -
   Bristol James Arthur Director   –       •      –    2020-01-02 4 AS $57.51 $899,468 D/D (15,553) 0 -11%     
   Bristol James Arthur Director   –       •      –    2020-01-02 4 OE $1.89 $29,395 D/D 15,553 15,553     -
   Taylor Michael Douglas Director   –       •      –    2020-01-02 4 AS $57.50 $5,413,113 D/D (93,578) 0 -11%     
   Taylor Michael Douglas Director   –       •      –    2020-01-02 4 OE $1.89 $176,862 D/D 93,578 93,578     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2020-01-02 4 AS $57.54 $441,748 D/D (7,641) 0 -11%     
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2020-01-02 4 OE $1.89 $14,441 D/D 7,641 7,641     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2019-12-23 4 S $68.21 $2,728,368 D/D (40,000) 0     -
   Kelly Thomas Patrick Chief Financial Officer   •       –      –    2019-12-23 4 OE $1.89 $75,600 D/D 40,000 40,000     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-12-12 4 AS $60.00 $1,861,740 I/I (31,029) 35,750     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-12 4 AS $60.00 $902,040 D/D (15,034) 0     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-12 4 OE $3.95 $59,384 D/D 15,034 15,034     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-12-10 4 AS $55.00 $6,751,360 D/D (122,752) 24,500     -
   Flynn Daniel Lee Chief Scientific Officer   •       –      –    2019-12-10 4 OE $1.89 $232,001 D/D 122,752 118,430     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-10 4 AS $55.00 $640,585 D/D (11,647) 0     -
   Morl Christopher John Chief Business Officer   •       –      –    2019-12-10 4 OE $3.95 $46,006 D/D 11,647 11,647     -
  290 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us